Jill M Ferdinands
Overview
Explore the profile of Jill M Ferdinands including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qasmieh S, Ferdinands J, Chung J, Wiegand R, Flannery B, Rane M, et al.
medRxiv
. 2025 Jan;
PMID: 39802800
The test-negative design (TND) is widely used to estimate COVID-19 vaccine effectiveness (VE). Biased estimates of VE may result from effects of at-home SARS-CoV-2 rapid diagnostic test (RDT) results on...
2.
Wiegand R, Fireman B, Najdowski M, Tenforde M, Link-Gelles R, Ferdinands J
Nat Commun
. 2024 Nov;
15(1):10062.
PMID: 39567531
Test-negative designs (TNDs) are used to assess vaccine effectiveness (VE). Protection from infection-induced immunity may confound the association between case and vaccination status, but collecting reliable infection history can be...
3.
Fowlkes A, Peretz A, Greenberg D, Hirsch A, Martin E, Levine M, et al.
Int J Infect Dis
. 2024 Oct;
149:107260.
PMID: 39395753
Objectives: Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent...
4.
Grohskopf L, Ferdinands J, Blanton L, Broder K, Loehr J
MMWR Recomm Rep
. 2024 Aug;
73(5):1-25.
PMID: 39197095
This report updates the 2023-24 recommendations of the Advisory Committee on Immunization Practices (ACIP) concerning the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2022;72[No. RR-2]:1-24)....
5.
Morris S, Grohskopf L, Ferdinands J, Reed C, Biggerstaff M
Epidemiology
. 2023 Feb;
34(3):345-352.
PMID: 36807266
Background: High-dose, adjuvanted, and recombinant influenza vaccines may offer improved effectiveness among older adults compared with standard-dose, unadjuvanted, inactivated vaccines. However, the Advisory Committee on Immunization Practices (ACIP) only recently...
6.
Begley K, Monto A, Lamerato L, Malani A, Lauring A, Talbot H, et al.
Clin Infect Dis
. 2023 Jan;
76(11):1980-1988.
PMID: 36694363
Background: Current understanding of severe respiratory syncytial virus (RSV) infections in adults is limited by clinical underrecognition. We compared the prevalence, clinical characteristics, and outcomes of RSV infections vs influenza...
7.
Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S, et al.
BMJ
. 2022 Oct;
379:e072141.
PMID: 36191948
Objective: To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, and by age and immunocompromised status. Design:...
8.
Grohskopf L, Blanton L, Ferdinands J, Chung J, Broder K, Talbot H, et al.
MMWR Recomm Rep
. 2022 Aug;
71(1):1-28.
PMID: 36006864
THIS REPORT UPDATES THE 2021-22 RECOMMENDATIONS OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) CONCERNING THE USE OF SEASONAL INFLUENZA VACCINES IN THE UNITED STATES: (MMWR Recomm Rep 2021;70[No. RR-5]:1-24)....
9.
Ferdinands J, Patel M
Vaccine
. 2022 Mar;
40(19):2797-2801.
PMID: 35331567
Benefit conferred by "enhanced" influenza vaccines is often measured by relative vaccine effectiveness, (rVE), which compares disease risk among groups of people who received alternative vaccines. Differences in attenuation of...
10.
Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Feb;
71(7):255-263.
PMID: 35176007
CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion of a primary mRNA vaccination series and that immunocompromised persons...